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Abstract
Background: A functional vascular network is essential for the survival, growth and spread of
solid tumours, making blood vessels a key target for therapeutic strategies. Combretastatin A-4
phosphate (CA-4-P) is a tubulin-depolymerising agent in Phase II clinical trials as a vascular
disrupting agent. Not much is known of the molecular effect of CA-4-P under tumour conditions.
The tumour microenvironment differs markedly from that in normal tissue, specifically with respect
to oxygenation (hypoxia). Gene regulation under tumour conditions is governed by hypoxia
inducible factor 1 (HIF-1), controlling angiogenic and metastatic pathways.
Methods: We investigated the effect of CA-4-P on factors of the upstream and downstream
signalling pathway of HIF-1 in vitro.
Results: CA-4-P treatment under hypoxia tended to reduce HIF-1 accumulation in a
concentration-dependent manner, an effect which was more prominent in endothelial cells than in
cancer cell lines. Conversely, CA-4-P increased HIF-1 accumulation under aerobic conditions in
vitro. At these concentrations of CA-4-P under aerobic conditions, nuclear factor κB was activated
via the small GTPase RhoA, and expression of the HIF-1 downstream angiogenic effector gene,
vascular endothelial growth factor (VEGF-A), was increased.
Conclusion: Our findings advance the understanding of signal transduction pathways involved in
the actions of the anti-vascular agent CA-4-P.
Background
All solid tumours depend on a functional vascular supply
for their growth, survival and metastatic spread [1]. Two
new classes of anti-cancer agents specifically target the
tumour blood vessels, namely anti-angiogenic agents,
which interfere with the formation of new blood vessel,
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blood vessels (for a recent review see [2]). Combretastatin
A-4 phosphate (CA-4-P), a tubulin-depolymerising agent
structurally related to colchicines, is in clinical trials as a
vascular disrupting agent. Phase I trials, started in 1998,
have established a maximum tolerated dose (MTD) in the
range of 52–68 mg/m2, and showed significant changes in
tumour perfusion in patients by positron emission tom-
ography (PET) and contrast-enhanced proton magnetic
resonance imaging (MRI) at these doses [3-5]. CA-4-P has
recently entered Phase II trials in combination with con-
ventional radiation and chemotherapy [6].
Combretastatin A-4 was originally isolated from the
South African bush willow Combretum caffrum. The phos-
phate derivative, CA-4-P, was subsequently synthesised as
the more soluble prodrug [7]. The exact mechanism of
action of CA-4-P is not yet understood. In vitro, CA-4-P
causes microtubule depolymerisation, which leads to
endothelial cell shape changes [8]. Other, more rapid
effects include activation of the small GTPase Rho A and
subsequent reorganization of the actin cytoskeleton, lead-
ing to an increase in endothelial monolayer permeability
to macromolecules [9]. Rho A has been linked to the acti-
vation of transcription factors, including NF-κB [10].
Further work in endothelial cells demonstrated that CA-4-
P damaged mitotic spindles, arrested cells at metaphase,
and led to the death of mitotic cells with a characteristic
G2/M DNA content, following prolonged drug exposures
[11]. Mitotic arrest was associated with elevated levels of
cyclin B1 protein and increased p34cdc2 activity.
In animal models, CA-4-P caused a prolonged and exten-
sive drop in blood flow in tumour vessels, with much less
effect in normal tissues [12]. A rapid rise in tumour vascu-
lar permeability was observed leading to a catastrophic
shutdown of the established tumour vasculature within
minutes of drug exposure, causing necrosis and secondary
tumour cell death [13].
CA-4-P treatment has been shown to increase tumour
hypoxia (low oxygen) within one hour of drug treatment,
as measured by Eppendorf oxygen electrode or with the
use of the hypoxia marker pimonidazole [14,15]. Severe
hypoxia is also known as an inherent characteristic of vir-
tually all solid tumours, including experimental and clin-
ical cancers, but not normal tissues. It has been correlated
with poor prognosis, a more aggressive phenotype,
increased metastases and resistance to therapy (see review
by [16]). Early in vitro work had analysed CA-4-P cytotox-
icity under 1% oxygen conditions (mild hypoxia), show-
ing an increase in cell kill under hypoxia [17]. Beyond
that, little is known of the effect of inherent tumour
hypoxia on CA-4-P activity, or the effect of CA-4-P on gene
expression.
Gene regulation under hypoxia is governed by the tran-
scription factor, hypoxia inducible factor 1 (HIF-1) (for a
review see [18]). HIF-1 is a heterodimer consisting of the
subunits HIF-1α and HIF-1β/ARNT. Regulation involves
ubiquitin-mediated, oxygen-dependent destruction of
HIF-1α. The product of the von Hippel Lindau (vHL)
tumour suppressor gene targets HIF-1α for oxygen-
dependent proteolysis, acting as the substrate recognition
component of an E3 ubiquitin ligase. In cancer, activity of
the HIF system is up-regulated by microenvironmental
hypoxia, growth factors and genetic changes, such as loss
of vHL [19].
Since HIF-1 is the global hypoxic regulator of gene expres-
sion, and since CA-4-P both induces and acts under
tumour hypoxia, we set out to determine the interactions
of CA-4-P, hypoxia and HIF-1, as well as upstream and
downstream factors of the HIF-1 signal transduction path-
way.
Methods
Tissue culture
Human T24 bladder carcinoma and SW1222 colon carci-
noma cells (American Type Culture Collection, Manassa,
VA) were maintained in Dulbecco's modified Eagle's
medium (DMEM, Life Technologies, Paisley, UK), 10%
foetal calf serum (FCS) and glutamine (2 mM) in a
humidified incubator, 37°C, in 5% CO2/air. Human
umbilical vein endothelial cells from pooled donors
(HUVECs, TCS CellWorks, Botolph Clayton, UK) were
cultured on gelatine coated dishes in M199 media (Invit-
rogen, Paisley, UK) supplemented with 20% FCS, 4 mM L-
glutamine, 20 μg/ml endothelial cell growth supplement
(First Link, Birmingham, UK), and 80 μg/ml heparin.
Only cells between the first and fourth passages were used
for experiments. Human dermal microvascular endothe-
lial cells (HDMECs, Clonetics, Cambrex, Wokingham,
UK) were cultured in EBM-2 media (Clonetics) containing
5% FCS, hydrocortisone, hFGF-B, VEGF, IGF-1, ascorbic
acid, hEGF and GA-1000 as supplied by the manufacturer
(Clonetics).
Cells were treated and analysed when they either reached
40–50% confluence (sparse) or 80–90% confluence
(dense). Sparse cells were actively dividing, whereas dense
cells approached quiescence as determined by fluores-
cence activated cell sorting (FACS) analysis (results not
shown). Densely growing endothelial cells were used to
mimic quiescent, and possibly more mature vessels,
whereas sparsely seeded cells were used as simple models
to mimic the angiogenic phase of blood vessels. In a sim-
ilar way, we studied sparsely and densely seeded tumourPage 2 of 11
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expression studies in the past [20].
HIF-1 induction
To achieve hypoxia and induce HIF-1, cells were plated in
6 cm oxygen impermeable Permanox dishes (Nalge,
Nunc, Loughborough, UK) at 1–5 × 105/dish (4–18 × 103/
cm2). Hypoxic conditions were achieved by placing the
dishes in an anaerobic glove cabinet (in an atmosphere of
5% CO2, 5% H2, 90% N2, with palladium catalyst; Don
Whitley Scientific LTD, Shipley, UK). The media pH was
monitored and found to be the same in the aerobic incu-
bator and the anaerobic glove cabinet. There was no sig-
nificant difference is cell viability between aerobic and
hypoxic cells over a 24 h period (results not shown).
Alternatively, the hypoxia-mimetic agent, CoCl2 (Sigma
Aldrich, Gillingham, UK), was used at 100 μM concentra-
tion for varying periods of time 0–24 h [21]. Maximum
HIF-1 accumulation was reached within 4 h of hypoxia or
CoCl2 treatment, and stayed at that level for up to 24 h,
and hence 4 h was used as the standard time for subse-
quent experiments.
Drug treatment
CA-4-P was synthesised in house (Dr. M Naylor et al., Gray
Cancer Institute; [7]) and used at 0.001, 0.01, 0.1, or 1 μM
in complete medium, avoiding excessive exposure to
light. The concentrations of CA-4-P used are clinically rel-
evant (CA-4 peak plasma concentration at a dose of 68
mg/m2 reached 2.26 μM; CA-4 concentration stayed
above 0.01 μM in plasma for over 10 h in those patients
[5]) and were shown to induce both morphological and
functional changes in endothelial cells in vitro [9]. CA-4-P
is the more soluble, phosphated, form of the active com-
pound CA-4. CA-4-P is commonly used for in vitro and in
vivo studies, where it is cleaved to the natural form by
endogenous phosphatases and taken up into cells [22].
The Rho kinase inhibitors Y27632 (10 μM; Welfide Cor-
poration (Osaka, Japan)) or HA1077 (10 μM; Calbio-
chem (Nottingham, United Kingdom)) were added to
HUVECs for 1 hour prior to treatment with CA-4-P.
HUVECs were incubated with the Rho A inhibitor C3
exoenzyme (10 μg/ml; Upstate (Dundee, Scotland)) for
12 hours before washing and treatment with CA-4-P. We
have previously used these concentrations and exposure
times, and shown them to be effective in preventing CA-
4-P-induced cytoskeletal changes [9].
Immunofluorescence
Cells were fixed and stained essentially as described previ-
ously [9]. Briefly, formalin-fixed and Triton-X-permeaba-
lised cells were stained with primary antibody (Ab) (anti-
HIF-1α at 1/250 (BD Biosciences, Cowley, UK), followed
by secondary Ab (biotinylated anti-mouse, Vector Labora-
tories, Peterborough, UK) and FITC – Avidin (Vector lab-
oratories) with DAPI (DNA stain, Vector Laboratories).
Slides were visualised on a Nikon Eclipse TE200 Micro-
scope.
Western blotting
For HIF-1 detection, denatured total cell lysates were pre-
pared as described previously [9]. Care was taken to
include both adherent and floating cells, although few
floating cells were observed. For NFκB studies, cellular
fractions were isolated using a NE-PER kit (Perbio, Cram-
lington, UK) according to manufacturer's instructions. For
Western blot analysis, equal amounts of protein (Pierce
Micro BCA kit, Rockford, IL) were separated on NuPAGE
4–12% Bis-Tris Gels (Invitrogen) and transferred to nitro-
cellulose membranes. Anti-HIF-1α (primary Ab at 1/250,
BD Biosciences) and secondary anti-mouse (HRP-
labelled, Dako, Ely, UK) antibodies, or goat anti-human
anti-NFκB (p65) antibody (Dako) and secondary anti-
goat (HRP-labelled, Dako) were used. Immunoreactive
bands were visualised by enhanced chemiluminescence
(ECL, Amersham-Biosciences, Chalfont St Giles, UK).
Equal protein loading was confirmed using EZBlue gel
stain (Sigma). Normalisation using actin staining was not
possible in this study, as CA-4-P acts directly on the actin
cytoskeleton [9].
Electrophoretic mobility shift assay (EMSA)
EMSAs were performed on nuclear fractions using an
EMSA kit for NFκB (Panomics, Cambridge Biosciences,
Cambridge, UK). Competition assays were performed in
the presence of 100-fold excess of cold (unlabelled) NFκB
probe. Supershift assays for p50 and p65 components
were performed by incubation of samples with antibodies
against p50 or p65 for 30 minutes prior to the addition of
probe.
Semi-quantitative real-time RT-PCR
RNA was extracted using Trizol (Invitrogen, Carlsbad, CA)
following manufacturer's instructions. Total RNA (1 μg)
was DNase-1 pre-treated (Invitrogen) immediately prior
to reverse-transcription using a SuperScript™ First-Strand
Synthesis System for RT-PCR (Invitrogen) according to
manufacturer's instructions. Polymerase chain reaction
(PCR) was carried out in a 25 μl reaction volume contain-
ing 1 μl of prepared cDNA, 10 μl RealMasterMix™ Probe
(Eppendorf, Hamburg, Germany), 200 nM of each LUX
FAM-labelled primer pair for the gene of interest (Invitro-
gen) and 100 nM of a commercial 18S LUX JOE-labelled
primer (Invitrogen). Real-time RT-PCR was carried out in
a Corbett Rotor-Gene 3000 thermal cycler (Mortlake, Aus-
tralia). Cycling parameters consisted of an initial denatur-
ation step at 95°C for 1 minute, followed by 45 cycles of
denaturation at 95°C for 20 s, primer annealing at 63°CPage 3 of 11
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20 s, followed by melt curve analysis. Primer sequences
for VEGF were as follows: Reverse primer (5'-3') CGA AGC
CAT GAA CTT CAC CAC TT [FAM] G; forward primer (5'-
3') GCT CTA CCT CCA CCA TGC CAA G.
Statistical analysis
The mean levels were compared between groups using
ANOVA. Where significant differences between groups
were identified, these were further explored using Fisher's
Least significant difference tests. A value of p < 0.05 was
considered significant.
Results
Cellular localisation of HIF-1
Since translocation of the HIF-1 heterodimer to the
nucleus is one of the steps characterising activation of
HIF-1 [23], we analysed the cellular localisation of HIF-1α
by immunofluorescence in T24 cancer cells (Figure 1).
Immunofluorescence analysis demonstrated a variation
in staining and nuclear localisation within the same cell
population. Following stimulation by hypoxia or its
mimetic agent, CoCl2, the tumour cells showed significant
nuclear localisation of HIF-1α (Figure 1B). Treatment of
hypoxic cells with CA-4-P (1 μM) did not appear to alter
localisation of HIF-1 relative to hypoxia alone (Figure
1B,1D). Drug treated T24 cells showed signs of apoptosis
(nuclear fragmentation) (Figure 1C,1D).
HIF-1 accumulation following hypoxic CA-4-P treatment
Using Western blot analysis, we confirmed that the HIF-
1α subunit accumulated in T24 cells subjected to hypoxia
or CoCl2 within 30 min and increased further up to a max-
imum at 4 h (remaining elevated up to 24 h), and
degraded rapidly, within 15 min, following re-oxygena-
tion (Figure 2A). Next, T24 and SW1222 cancer cells, as
well as HUVEC and HDMEC endothelial cells in vitro were
exposed to CA-4-P under hypoxia, and the effect on HIF-
1 protein accumulation was analysed (Figure 2B). West-
ern blot analysis of treated cell extracts indicated a trend
towards a CA-4-P concentration- dependent reduction in
HIF-1 accumulation under hypoxia. This effect was more
prominent in the endothelial cells than the cancer cell
lines. Also, the sparsely plated SW1222 colon cell line dis-
played some ambiguity in HIF-1 staining. Overall, the
reduction in HIF-1 accumulation was seen whether cells
were treated under hypoxia (Figure 2B) or with CoCl2
(results not shown), independent of cell density. This
effect was evident whether cells were hypoxia-stimulated
for 4 h at the start (results not shown) or end (Figure 2B)
of the 24 h CA-4-P treatment period. A period of hypoxia
(up to 24 h) did not change the number of viable or
necrotic cells (trypan blue exclusion assays, results not
shown).
To more closely mimic the clinical situation, we also ana-
lysed the effect of a short exposure to CA-4-P. CA-4-P in
patients is rapidly converted to the active compound CA-
4, which has a terminal plasma half-life of 3.3 h [24]. The
Western blot data showed that even short (1 h) pre-expo-
sure to CA-4-P under aerobic conditions reduced subse-
quent hypoxia-induced HIF-1 accumulation in T24 cells
48 h later (Figure 2C). A similar result was obtained at 4 h
in sparsely but not densely plated cells.
HIF-1 accumulation following normoxic CA-4-P treatment
We exposed cells to 1 μM CA-4-P for varying periods from
30 min to 24 h, and observed an increase in HIF-1 accu-
mulation under aerobic conditions (Figure 3). HIF-1 accu-
mulation increased over time in both T24 tumour cells
and HUVECs. Control cultures (without CA-4-P) showed
no significant increase in HIF-1 accumulation over this
time period (results not shown).
NFκB activation via Rho A following CA-4-P treatment
In order to determine the upstream signalling pathway
involved in the aerobic stabilisation of HIF-1, we analysed
NFκB activation by CA-4-P. Western blot analysis demon-
strated that incubation of HUVEC with CA-4-P caused a
dose dependent transfer of the p65 component of NFκB
from the cytoplasmic fraction to nuclear fraction within 1
h (Figure 4A). Further analysis, using electrophoretic
mobility shift assays (EMSA), demonstrated little consti-
tutive binding of control nuclear extracts to an oligonucle-
otide containing the NFκB consensus sequence (Figure
4B). Following treatment with CA-4-P, two densely
labelled complexes were observed (Figure 4B). These
bands could be competed out by an excess of unlabeled
(cold) NFκB probe. NFκB-DNA complex formation in
response to CA-4-P appeared to peak at one hour, and was
reduced to near control levels four hours post stimulation
(results not shown). We performed Supershift assays
using specific antibodies to p65 and p50 to reveal the
identities of the protein in the CA-4-P-induced NFκB
binding complex. Incubation with antibody to p50 or p65
resulted in a further shift of the p50-DNA complex, and
the disappearance of the p65-DNA complex (Figure 4B),
indicating that CA-4-P activates NFκB in the form of a
p50·p65 heterodimer in HUVEC.
Incubation of HUVEC with the Rho A inhibitor C3 exoen-
zyme prevented the formation of CA-4-P-induced com-
plexes. However, incubation of HUVEC with the Rho
kinase inhibitors Y27632 and HA1077, prior to treatment
with CA-4-P, had no effect on the formation of the NFκB
complex (Figure 4B).
VEGF induction following normoxic CA-4-P treatment
In order to determine whether the observed CA-4-P-
induced modulation of HIF-1 accumulation had an effectPage 4 of 11
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expression of vascular endothelial growth factor (VEGF-A)
by real time RT-PCR. As expected, T24 cells and HUVECs
treated with 100 μM CoCl2 showed a significant increase
in VEGF expression of 2.9 and 3.5-fold, respectively, com-
pared to aerobic controls (Figure 5). Cells exposed to CA-
4-P under aerobic conditions for 24 h (T24, p < 0.05) or 2
h (HUVEC, p < 0.05) showed an increase in VEGF expres-
sion of 1.9 and 2.0-fold, respectively, reflecting HIF-1
accumulation under aerobic conditions. T24 cells exposed
to CA-4-P for only 2 h, however, showed no modulation
of VEGF expression (Figure 5A). The combination of CA-
Effect of CA-4-P on cellular HIF-1 localisation and nuclear morphologyFigure 1
Effect of CA-4-P on cellular HIF-1 localisation and nuclear morphology. Immunofluorescent staining showed limited nuclear 
HIF-1 accumulation of unstimulated T24 cells (A) and CA-4-P-treated aerobic cells (C), with significant accumulation in hypoxic 
(B) and CA-4-P-treated hypoxic cells (D). CA-4-P treatment (1 μM) induced nuclear fragmentation (circled), but did not nota-
bly alter HIF-1 localisation. Identical microscopic fields of DAPI-stained nuclei (left) and HIF-1α stained cells (right) are shown.
A unstimulated B hypoxia
DAPI HIF-1α DAPI HIF-1α
C CA-4-P D hypoxia, CA-4-P  
DAPI HIF-1α DAPI HIF-1αPage 5 of 11
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HIF-1 modulation by hypoxia and CA-4-PFigure 2
HIF-1 modulation by hypoxia and CA-4-P. A: Hypoxic accumulation and normoxic degradation of HIF-1.  Western blot analysis 
showed that T24 tumour cells exposed to increasing lengths of time under hypoxia accumulated HIF-1a, and HIF-1a degraded 
rapidly under aerobic conditions. B: Increasing concentrations of CA-4-P modulate the hypoxic accumulation of HIF-1. Sparse 
and dense endothelial and tumour cells were treated for 24h with increasing concentrations of CA-4-P (0 - 1mM), and sub-
jected for the final 4h to hypoxia, prior to protein extraction and detection of HIF-1a by Western blot analysis. Similar results 
were obtained in >3 independent experiments; representative photographs are shown. C: Short pre-exposure to CA-4-P 
reduces hypoxic HIF-1 accumulation. T24 tumour cells exposed for 1h to CA-4-P showed a reduction in hypoxic HIF-1 accu-
mulation 4h and 48h later, compared to untreated cells.
HUVEC
HDMEC
SW1222
T24
sparse dense
CA-4-P (μM) 0
0.0
1 0.1 1 0 0.0
1 0.1 1
A
B
C
CA-4-P (μM) 0 1 0 1 0 1 0 1
anoxia   15min     1h       2h       4h       24h0h     30min  1h      2h       4h      6h     24h
Anoxic accumulation Normoxic degradation
sparse dense sparse dense
4h 48h
BMC Cancer 2006, 6:280 http://www.biomedcentral.com/1471-2407/6/2804-P for 24 h and CoCl2 for 4 h in T24 cells did not increase
VEGF above CoCl2-treatment alone (Figure 5A)
Discussion
We analysed the effect of CA-4-P on the transcription fac-
tor HIF-1, as well as members of its upstream and down-
stream signal transduction pathway in vitro. Our results
have demonstrated that CA-4-P could differentially mod-
ulate members of the HIF-1 signal transduction pathway
depending on the cell's oxygenation status. Although the
findings require further systematic follow-up, they are val-
uable for generating new hypotheses.
A trend towards a CA-4-P-concentration dependent reduc-
tion in hypoxic HIF-1 accumulation was observed. The
significance of these in vitro findings is not yet clear. How-
ever, these results have some anecdotal support from a
preliminary in vivo study indicating that therapeutic CA-4-
P doses reduced HIF-1 accumulation in SW1222
xenografted tumours at 24 h but increased HIF-1 at 4 h
after treatment (results not shown).
The preliminary in vivo data can be explained by a simple
model, whereby acute hypoxia is caused by CA-4-P-
induced-vascular disruption [14,15], resulting in the early
accumulation of HIF-1, followed at later times by the loss
of hypoxic cells by necrosis, with their accumulated HIF-
1, resulting in an apparent reduction in HIF-1 protein.
Further in vivo work is clearly required.
There also appeared to be a more prominent effect in
endothelial cells compared to tumour cells. Endothelial
PER-ARNT-SIM domain protein (EPAS), also known as
HIF-2α, has 48% sequence identity to HIF-1α, and was
initially shown to be limited to the endothelium of mouse
embryos [25]. Since then, both HIF-1α and HIF-2α were
detected in most human cells, and both activate a range of
hypoxia response elements with similar efficacy. Impor-
tantly for our research, a study using short interfering
RNAs against the two HIFs established that in endothelial
cells, hypoxia-inducible gene expression of a panel of
genes was critically dependent only on HIF-1, and not
HIF-2 [26]. Hence, our result demonstrating CA-4-P mod-
ulation of HIF-1α in endothelial cells is relevant. In addi-
tion, we have found no cell type or condition-specific
accumulation of HIF-2α across our panel of cells and cell
lines (results not shown).
Our findings, of an increase in HIF-1 in response to nor-
moxic CA-4-P treatment, agree with data from Jung et al
[27] who used the microtubule disrupting agents colchi-
cine (1 μM), vinblastine (0.1 μM) and nocodazole (10
μM). That group showed that HIF-1 induction was
dependent on transcription and on activation of NFκB.
Our work supports their data by demonstrating transloca-
tion and subsequent binding of NFκB to specific DNA
sequences following CA-4-P treatment. Hence it is likely
that CA-4-P induction of HIF-1 also acts through NFκB,
similar to other tubulin disrupting agents. Our data fur-
ther show that NFκB activation by CA-4-P was dependent
on Rho A. This link is supported by previous work using
thrombin showing a direct signal transduction via Rho A
to NFκB [28]. However, in contrast to our previous find-
ings for other signalling pathways, which showed a role
CA-4-P induces the accumulation of HIF-1 under aerobic conditionsFigure 3
CA-4-P induces the accumulation of HIF-1 under aerobic conditions. Tumour and endothelial cells showed a time-dependent 
increase in HIF-1 accumulation under aerobic conditions during treatment with 1 μM CA-4-P. Similar results were obtained 
from 3 independent experiments; representative photographs are shown.
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HUVEC
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induced NFκB activation was shown to be independent of
Rho kinase. This suggests that other downstream effectors
of Rho A may be involved in NFκB activation.
Our results demonstrated that VEGF expression mirrored
CA-4-P-induced HIF-1 accumulation under aerobic con-
ditions, indicating that the accumulated HIF-1 is active
and able to regulate transcription of downstream genes.
VEGF is the most potent angiogenic growth factor in solid
tumours. It also has a range of other functions, including
induction of vascular permeability and supporting sur-
vival of endothelial cells. Although the vasculature of
solid tumours is known to be leaky, a further increase in
vascular permeability due to CA-4-P treatment has been
demonstrated in vivo [13]. Our findings in this paper are
consistent with published data on another combretastatin
family member, OXI4503 [29], showing that elevated
tumour vessel permeability was accompanied by an
increase in VEGF from 1 hr post drug treatment in vivo.
Hence, our observed increase in VEGF expression and
HIF-1 accumulation under aerobic conditions with clini-
cally relevant concentrations of CA-4-P may in part
explain previous in vivo findings. It is interesting to note
that in our work on VEGF expression, endothelial cells
CA-4-P induces NFkB nuclear translocation and activationFigure 4
CA-4-P induces NFkB nuclear translocation and activation. A: CA-4-P induces NFkB translocation from the cytoplasm to the 
nucleus. Western blot analysis of CA-4-P treated aerobic HUVEC demonstrating   translocation of NFkB (p65) protein from 
the cytoplasmic to the nuclear   fraction within 1 h in a dose dependent manner. C: cytoplasmic fraction, N:   nuclear fraction. 
B: CA-4-P induces NFkB activation via Rho A, but not Rho kinase. EMSA showed that CA-4-P induced NFkB-DNA complex 
formation in aerobic   HUVEC. Supershift analysis using antibodies against NFkB components resulted in a further retardation 
of the p50 band and loss of the p65 band. Treatment with Rho kinase inhibitors (Y27632 and HA1077) demonstrated no effect 
on NFkB, whereas treatment with the Rho A inhibitor C3 prevented  NFkB activation by CA-4-P. (1) vehicle control, (2) 
0.1mM CA-4-P, (3) +   cold probe, (4) + p50 Ab, (5) + p65 Ab, (6) + Y27632, (7) + HA1077, (8) + C3.
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CA-4-P-modulation of the angiogenic growth factor VEGFFigure 5
CA-4-P-modulation of the angiogenic growth factor VEGF. Expression of VEGF was detected by real time RT-PCR in T24 blad-
der carcinoma (A) and HUVEC (B) following aerobic treatment: (1) control, (2) 2 h CA-4-P (1 μM), (3) 24 h CA-4-P (1 μM), 
(4) 4 h CoCl2 (100 μM), (5) 24 h CA-4-P and 4 h CoCl2. RNA was extracted from two flasks each, and > 3 independent real 
time PCR reactions were performed on each; average and SEM are shown; * p < 0.05 compared to control; # p < 0.05 com-
pared to (3).
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ing requires further investigation.
Conclusion
HIF-1 protein has been reported in all human tissue and
organs assayed, and shown to be over-expressed in many
human tumours, including breast, bladder and colon car-
cinomas [19,30]. Our data has shown that CA-4-P affects
members of the HIF-1 signal transduction pathway. There
appears to be support for both increases and decreases in
HIF-1 accumulation in vitro, and both scenarios have pos-
sible implications for tumour biology, as HIF-1 is the
main regulator of a range of angiogenic, vasoactive and
metastatic factors [16]. The impact of these findings on
treatment response, if any, remains to be determined.
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